Back to Search Start Over

Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?

Authors :
Jean-François Chatal
Jacques Barbet
Françoise Kraeber-Bodéré
Centre de Recherche en Cancérologie Nantes-Angers (CRCNA)
Centre Hospitalier Universitaire d'Angers (CHU Angers)
PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes)
ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public)
This work has been supported in part by grants from the French National Agency for Research, called 'Investissements d’Avenir' IRON Labex no. ANR-11-LABX-0018-01 and ArronaxPlus Equipex no. ANR-11-EQPX-0004.
ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011)
ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011)
Bernardo, Elizabeth
Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID
Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID
Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA )
CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes )
ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] ( Institut de Recherche Public )
ANR-11-LABX-0018/11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie ( 2011 )
ANR-11-EQPX-0004/11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé ( 2011 )
Source :
Journal of Nuclear Medicine, Journal of Nuclear Medicine, Society of Nuclear Medicine, 2016, 57 (3), pp.329-331. ⟨10.2967/jnumed.115.167247⟩, Journal of Nuclear Medicine, 2016, 57 (3), pp.329-331. ⟨10.2967/jnumed.115.167247⟩, Journal of Nuclear Medicine, Society of Nuclear Medicine, 2016, 57 (3), pp.329-331. 〈10.2967/jnumed.115.167247〉
Publication Year :
2016
Publisher :
HAL CCSD, 2016.

Abstract

Radioimmunotherapy is a targeted molecular therapy that bears on radiobiologic and immunologic processes, without cross-resistance with other anticancer cytotoxic drugs. Since the first reports in the literature at the beginning of the 1980s, radioimmunotherapy techniques have significantly

Subjects

Subjects :
0301 basic medicine
Oncology
medicine.medical_specialty
Immunoconjugates
Receptor, ErbB-2
medicine.medical_treatment
Breast Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
Clinical success
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
Targeted Molecular Therapy
medicine
Animals
Humans
Radiology, Nuclear Medicine and imaging
ComputingMilieux_MISCELLANEOUS
business.industry
Radioimmunotherapy
3. Good health
ErbB Receptors
030104 developmental biology
030220 oncology & carcinogenesis
Immunology
Radiopharmaceuticals
business

Details

Language :
English
ISSN :
01615505 and 15355667
Database :
OpenAIRE
Journal :
Journal of Nuclear Medicine, Journal of Nuclear Medicine, Society of Nuclear Medicine, 2016, 57 (3), pp.329-331. ⟨10.2967/jnumed.115.167247⟩, Journal of Nuclear Medicine, 2016, 57 (3), pp.329-331. ⟨10.2967/jnumed.115.167247⟩, Journal of Nuclear Medicine, Society of Nuclear Medicine, 2016, 57 (3), pp.329-331. 〈10.2967/jnumed.115.167247〉
Accession number :
edsair.doi.dedup.....94edcb3515c3e2faae290481fe808bc9
Full Text :
https://doi.org/10.2967/jnumed.115.167247⟩
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details